MX338247B - Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. - Google Patents

Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Info

Publication number
MX338247B
MX338247B MX2012000083A MX2012000083A MX338247B MX 338247 B MX338247 B MX 338247B MX 2012000083 A MX2012000083 A MX 2012000083A MX 2012000083 A MX2012000083 A MX 2012000083A MX 338247 B MX338247 B MX 338247B
Authority
MX
Mexico
Prior art keywords
storage disease
glycogen
treatment method
disease treatment
polysaccharide storage
Prior art date
Application number
MX2012000083A
Other languages
English (en)
Inventor
Charles Roe
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of MX338247B publication Critical patent/MX338247B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar enfermedad de almacenamiento de glucógeno al administrar una cantidad efectiva de una composición que incluye ácidos grasos de carbono impar cetogénicos que alivian los síntomas de estas enfermedades.
MX2012000083A 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. MX338247B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58550204P 2004-07-02 2004-07-02
PCT/US2005/023524 WO2006014353A2 (en) 2004-07-02 2005-07-01 Glycogen or polysaccharide storage disease treatment method

Publications (1)

Publication Number Publication Date
MX338247B true MX338247B (es) 2016-04-07

Family

ID=35787579

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012000083A MX338247B (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
MX2007000304A MX2007000304A (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007000304A MX2007000304A (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Country Status (5)

Country Link
US (9) US8106093B2 (es)
EP (2) EP1773317A4 (es)
CA (3) CA2784420C (es)
MX (2) MX338247B (es)
WO (1) WO2006014353A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
CA2784420C (en) * 2004-07-02 2020-11-10 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US20070203907A1 (en) * 2006-02-03 2007-08-30 Polyglot Systems, Inc. User interface for entry of step changes
US20080132571A1 (en) * 2006-09-26 2008-06-05 Baylor Research Institute Nutrient Sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
MX2008000951A (es) * 2008-01-21 2008-04-21 Rodolfo Jose Medeles Orozco Suplemento energetico para nutricion animal??.
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
US20110044964A1 (en) * 2009-08-24 2011-02-24 Hero Nutritionals, LLC Plant-based omega chewable supplement
CA2785714C (en) * 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
EP2579867A4 (en) * 2010-06-14 2014-03-19 Baylor Res Inst TRIHEPTANOIN REGIME FOR THE TREATMENT OF ADULT POLYGLUCOSAN BODY DISEASE (APBD)
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
JP2016504323A (ja) 2012-12-13 2016-02-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ グルコーストランスポータ１欠乏の治療のためのトリヘプタノイン
WO2015073803A1 (en) 2013-11-14 2015-05-21 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
TWI640327B (zh) * 2013-11-14 2018-11-11 美商奧崔基尼克斯製藥公司 三酸甘油酯之固體組合物及其用途
US10328045B2 (en) 2014-09-12 2019-06-25 Children's Medical Center Corporation, Inc. Dietary emulsion formulations and methods for using the same
US20180000084A1 (en) * 2014-12-30 2018-01-04 Dow Agrosciences Llc Use of picolinamide compounds with fungicidal activity
US20180103655A1 (en) * 2016-10-18 2018-04-19 Ferrara Candy Company Hard Candy with Gummy Center and Systems and Methods for Making Same
US10238618B2 (en) * 2016-12-29 2019-03-26 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of anemia
WO2019032959A1 (en) * 2017-08-10 2019-02-14 The Children's Medical Center Corporation METHODS AND COMPOSITIONS RELATING TO EMULSIONS COMPRISING FISH OIL AND / OR OMEGA-3 FATTY ACIDS
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
KR20200075815A (ko) 2017-10-23 2020-06-26 에피트래커, 인코포레이티드 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도
SG11202004336VA (en) 2017-12-01 2020-06-29 Ultragenyx Pharmaceutical Inc Creatine prodrugs, compositions and methods of use thereof
US10874131B2 (en) 2017-12-22 2020-12-29 Heliae Development Llc Human and non-human animal use of microbial anaplerotic oil
WO2019226572A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020014428A1 (en) 2018-07-11 2020-01-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids
CA3110724A1 (en) 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
WO2023211755A1 (en) * 2022-04-28 2023-11-02 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697563A (en) 1970-06-29 1972-10-10 Inst Chemioterapico Italiano S (3,4,5-trimethoxy-benzamido)-alkanoic acids for prophylaxis and treatment of cardiac disorders
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4042684A (en) 1976-03-23 1977-08-16 Annika Britt Kahm Dietetic beverage
US4777045A (en) 1985-07-26 1988-10-11 Nabisco Brands, Inc. High bran snack
US4753963A (en) * 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
CA1302280C (en) 1986-04-21 1992-06-02 Jon Joseph Kabara Topical antimicrobial pharmaceutical compositions and methods
WO1989000559A1 (en) 1987-07-17 1989-01-26 Schering Aktiengesellschaft Berlin Und Bergkamen 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs
US4871557A (en) * 1988-06-15 1989-10-03 Amway Corporation Granola bar with supplemental dietary fiber and method
US4981687A (en) 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5153221A (en) 1990-10-05 1992-10-06 Elena Avram Method for the treatment of acquired immune deficiency syndrome
DE4439947A1 (de) 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE19615035A1 (de) * 1996-04-17 1997-10-23 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Glycerinestern von alpha-Hydroxycarbonsäuren und gesättigten Fettsäuren
US5908631A (en) * 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
PL193929B1 (pl) * 1998-03-23 2007-04-30 Gen Mills Inc Jadalny produkt na bazie skrobi, kompozycja odżywcza oraz sposób wytwarzania jadalnego produktu
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
IL144645A0 (en) * 1999-02-05 2002-05-23 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
TWI240616B (en) 2000-05-26 2005-10-01 Ajinomoto Kk Feed for livestock
US6746698B2 (en) * 2000-07-06 2004-06-08 Grain Processing Corporation Animal feed, method for preparing animal feed, and method for feeding an animal
CA2784420C (en) 2004-07-02 2020-11-10 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
EP2579867A4 (en) * 2010-06-14 2014-03-19 Baylor Res Inst TRIHEPTANOIN REGIME FOR THE TREATMENT OF ADULT POLYGLUCOSAN BODY DISEASE (APBD)

Also Published As

Publication number Publication date
US20060004099A1 (en) 2006-01-05
US8697748B2 (en) 2014-04-15
CA2573054A1 (en) 2006-02-09
MX2007000304A (es) 2007-06-15
CA2573054C (en) 2012-10-09
US20130005818A1 (en) 2013-01-03
EP3300727A1 (en) 2018-04-04
US8106093B2 (en) 2012-01-31
US20210145784A1 (en) 2021-05-20
US20140288175A1 (en) 2014-09-25
US20170239205A1 (en) 2017-08-24
CA2784585A1 (en) 2006-02-09
US20200009102A1 (en) 2020-01-09
US9186344B2 (en) 2015-11-17
WO2006014353A2 (en) 2006-02-09
CA2784420C (en) 2020-11-10
EP1773317A4 (en) 2012-10-03
US20220395482A1 (en) 2022-12-15
US20160030375A1 (en) 2016-02-04
EP1773317A2 (en) 2007-04-18
US20190083442A1 (en) 2019-03-21
CA2784420A1 (en) 2006-02-09
WO2006014353A3 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
MX2007000304A (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
BRPI0514253A (pt) terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2007053661A3 (en) Uses of anti-cd40 antibodies
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
NO20065915L (no) Forbedring av barriereintegritet i HIV-pasienter
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
NZ597031A (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
EP4285988A3 (en) Treating fibrosis by inhibiting tl1a
ZA202210079B (en) Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
WO2007147868A3 (en) Prevention of muscle atrophy
TW200640467A (en) Compounds and uses thereof